Arteries and veins are specified by antagonistic transcriptional programs. However, during development and regeneration, new arteries can arise from pre-existing veins through a poorly understood process of cell fate conversion. Here, using single-cell RNA sequencing and mouse genetics, we show that vein cells of the developing heart undergo an early cell fate switch to create a pre-artery population that subsequently builds coronary arteries. Vein cells underwent a gradual and simultaneous switch from venous to arterial fate before a subset of cells crossed a transcriptional threshold into the pre-artery state. Before the onset of coronary blood flow, pre-artery cells appeared in the immature vessel plexus, expressed mature artery markers, and decreased cell cycling. The vein-specifying transcription factor COUP-TF2 (also known as NR2F2) prevented plexus cells from overcoming the pre-artery threshold by inducing cell cycle genes. Thus, vein-derived coronary arteries are built by pre-artery cells that can differentiate independently of blood flow upon the release of inhibition mediated by COUP-TF2 and cell cycle factors.
The ability of cells to switch fates and acquire new identities is critical for organogenesis and regeneration, but the mechanisms that underlie cell fate conversions are poorly understood. The vasculature is a model for this process because it initially differentiates into arteries and veins whose transcriptional networks antagonize each other (Notch signalling maintains arteries while COUP-TF2 maintains veins 1, 2 ). However, during development and regeneration, veins can become the source of new arteries [3] [4] [5] [6] . The timing and requirements of vein-to-artery conversions are not known, but could inform artery regeneration.
In mice, a portion of the coronary arteries of the heart develop from a vein called the sinus venosus (SV; Fig. 1a ). During embryogenesis, endothelial cell-lined angiogenic sprouts migrate from the SV to fill the heart with an immature coronary vessel plexus 4 . This plexus unites with plexus vessels from the endocardium 4, 7, 8 , and, together, they remodel into arteries, capillaries and veins. The plexus lacks blood flow until it attaches to the aorta, and arterial morphogenesis requires this event, suggesting that blood flow initiates artery development [8] [9] [10] [11] . However, it has been difficult to delineate cell fate changes during coronary angiogenesis owing to the limited number of molecular markers and bulk transcriptional analyses of heterogeneous populations.
Single-cell RNA sequencing (scRNA-seq) can overcome this limitation by producing single-cell-resolution maps of developmental transitions. Here, we developed a statistical test that categorizes subpopulations within scRNA-seq data sets as continuous or discrete to identify candidate developmental transitions. Computational or in vivo analysis of the SV-to-coronary transition revealed that SV cells of the mouse heart undergo a gradual conversion from vein to artery before a subset crosses a threshold to differentiate into pre-artery cells. Pre-artery cells differentiated before blood flow from the SV and endocardium and produced a large portion of coronary arteries. COUP-TF2 blocked progression to the pre-artery state through activation of cell cycle genes, which ultimately inhibited artery development. Understanding this and other cell fate switches and inhibitory signals will advance our knowledge of tissue development and could improve regenerative medicine.
Finding developmental transitions in scRNA-seq data
We performed a two-step analysis that identified and clustered cell subtypes by iterative robust principal component analysis (rPCA), and then subjected clusters to a pairwise discreteness test (Fig. 1b ). First, cell subtype clusters were manually defined on the basis of unique gene expression patterns and cell separation in multiple iterations of rPCA 12 (Fig. 1b) . rPCA was better than classical PCA at separating small subpopulations of cells 13 (Extended Data Fig. 1a ). We also replaced default principal component scores with a sum of the top 60 genes score because it was less correlated with technical artefact and better correlated with cluster-specific genes (Extended Data Fig. 1b, c) . Cell cycle heterogeneity was also removed (Extended Data Fig. 1d ), and plots were inspected to confirm the absence of doublets (Extended Data Fig. 1e ). This process resulted in cell clusters that correlate well with genes that define cell identity, and not with cell cycle heterogeneity or technical artefact (Extended Data Fig. 1c, d ).
Article reSeArcH in high resolution by observing gene expression changes across continuous populations (Fig. 1b) .
We used this pipeline to analyse 843 ApjCreER lineage-labelled (Cre expressed in SV) cardiac endothelial cells from hearts removed from mouse embryos at embryonic day 12.5 (E12.5) (Extended Data Fig. 1g ). Our data set contained endothelial cells from the SV, SV-derived coronary vessels, venous valves, valve mesenchyme, and some ventricular endocardial cells (Extended Data Fig. 1i, j) . Clustering and the pairwise discreteness test revealed a continuum between coronary vessel subtypes, the SV, venous valves, ventricular endocardium, and mesenchyme (Pdgfra + , Pecam1 low/− ) ( Fig. 1c and Extended Data Fig. 1i-k) . These associations are consistent with anatomical relationships (SV is adjacent to venous valves and endocardium) and previous lineage tracing experiments (SV transitions into coronary vessels and endocardium transitions into mesenchyme) 8, 11, [14] [15] [16] [17] . Thus, our pipeline can identify subpopulations and recapitulate known developmental transitions and anatomical relationships.
Pre-artery cells differentiate before blood flow
We analysed the developmental transition linking SV coronary progenitors (SVc) and coronary vessels ( Fig. 1c , dotted line). Only the SVc was included because clustering indicated that the SV had two domains (Fig. 1c ), and this was confirmed using immunofluorescence and in situ hybridization (Extended Data Fig. 2a-f ). The SVc was anatomically and transcriptionally continuous with coronary vessels, whereas the SVv (SV valve proximal) was continuous with venous valves (Fig. 1c , Extended Data Fig. 2d, f) . Therefore, rPCA of the SVc and coronary vessels was performed to study the SVc-coronary vessel continuum (Fig. 1d) .
Unexpectedly, the SVc-coronary vessel continuum identified cells that were transcriptionally distinct and expressed genetic markers of mature arterial cells (Fig. 1d ). We previously reported 4 that plexus cells express arterial genes such as Dll4 and Efnb2, but these are also expressed in angiogenic vessels, and are not artery-specific 18, 19 . The scRNA-seq analysis revealed that, within the Dll4 + domain, some cells had initiated a distinctive transcriptional program, shifting away in the rPCA plot ( Fig. 1d ). Cells within this subset specifically expressed mature artery-specific genes, including Cx40 (also known as Gja5) (Fig. 1d ). Analysis of multiple arterial and venous genes in single cells or as averages within clusters (defined in Extended Data Fig. 2g ) revealed that many arterial genes were either specific to or significantly increased in the Cx40 + cluster ( Fig. 1d and Extended Data Fig. 3a, b ). Multiple venous genes were either completely depleted or significantly downregulated ( Fig. 1d and Extended Data Fig. 3c, d) . Comparison of expression between the SVc and arterial populations revealed that SV-derived cells showed an extensive switch towards arterial fate (Fig. 1e ).
We next compared E12.5 arterial cells with adult coronary vessel cells. Each embryonic cell was matched to the adult cell to which it was most similar within the artery-capillary-vein continuum formed by adult coronary vessels 20 (Extended Data Fig. 3e -g). E12.5 artery cells were most similar to adult arterial cells, whereas coronary vessel plexus cells were most similar to adult capillaries and veins (Extended Data Fig. 3h ). We also found that E12.5 and adult artery populations were enriched for nearly the same artery markers (Supplementary Table 1 ). The exception was Notch1 (enriched only in adults), possibly because blood flow upregulates Notch1 21 , and E12.5 is before the onset of coronary perfusion. Thus, a subpopulation of plexus cells undergo a transcriptional shift to resemble mature arteries before the presence of arterial vessels or blood flow, prompting us to term them pre-artery cells.
The scRNA-seq also identified new arterial genes (Extended Data Fig. 4a ). Slc45a4 marked pre-artery cells at early stages and was later specific to mature embryonic arteries (Extended Data Fig. 4b, c ). It was also enriched in adult coronary artery cells (Extended Data Fig. 4a ). We found other genes to be enriched in pre-artery cells (Extended Article reSeArcH Data Fig. 4d ). Of these, Mecom and Igfbp3 marked arteries in adults (Extended Data Fig. 4d ).
Location, origins, and fate of pre-artery cells
In late embryonic stages (E17.5), CX40 is specific to mature arteries (Extended Data Fig. 5a ). By contrast, whole-mount immunostaining at early stages revealed that a small population of CX40 + cells first appeared at E12.5. These cells were interspersed within the intramyocardial plexus and expanded by E13.5 ( Fig. 2a, b ). Localization of additional pre-artery genes confirmed this result (Extended Data Fig. 5b ). The absence of CX40 + cells in the SV and their presence in the coronary vessel plexus agreed with clustering and pairwise analysis showing that pre-artery cells were continuous only with the coronary vessel plexus (Fig. 1c ). Defining clusters using Seurat showed similar results (Extended Data Fig. 6a ), although clusters were not as precise and were associated with cell cycle genes (Extended Data Fig. 6b , c). Thus, coronary angiogenesis involves the specification of single arterial endothelial cells within the intramyocardial plexus ( Fig. 1b) .
Although our scRNA-seq investigated only SV-derived vessels, lineage tracing revealed that coronary arteries are derived from both the SV and the endocardium 22 (Extended Data Fig. 6d ). Single CX40 + cells were detected in the plexus from both sources ( Fig. 2c ), indicating that pre-artery specification occurs during both SV and endocardium angiogenesis.
Cx40CreER Rosa tdTomato embryos were used for lineage tracing of pre-artery cells (tamoxifen, E11.5; Extended Data Fig. 6e , f). CX40 + pre-artery cells were later found in arteries, but not veins ( Fig. 2d, e ). A few capillaries were lineage-traced, indicating that pre-artery cells could revert to a capillary fate ( Fig. 2d ). Dosing at E10.5 ensured that our result was not due to persistent tamoxifen (Extended Data Fig. 6g ), and clonal level labelling confirmed the lineage data (Extended Data Fig. 6h ). Notably, at postnatal day (P)8, the right and left coronary artery branches were heavily lineage-labelled in hearts from mice dosed at E11.5; only the most distal tips were unlabelled ( Fig. 2f and Extended Data Fig. 6i ). Thus, pre-artery cells build a large portion of mature coronary arteries.
Pre-artery cells first appeared before blood flow, but they were abundant in the plexus through E14.5 (Extended Data Fig. 7c ), suggesting that specification could continue after coronary perfusion. To investigate this possibility, we used Cre lines that specifically label either coronary vessel plexus (ApjCreER) or pre-artery (Cx40CreER) cells (Extended Data Fig. 7a ) and induced labelling at various times (Extended Data Fig. 7b ). Labelling of the coronary vessel plexus at E12.5 or E13.5 lineage-traced a small number of pre-artery cells (Extended Data Fig. 7d, e ). However, when the coronary vessel plexus was labelled at E14.5, there was no tracing into artery main branches and very little in the tips (Extended Data Fig. 7f, h ). Conversely, labelling at E14.5 with Cx40CreER lineage-traced most left and right coronary artery branches (Extended Data Fig. 7g, h) . Finally, inducing labelling with Cx40CreER at E16.5 resulted in few capillary cells being labelled at embryonic and postnatal stages (Extended Data Figs. 6j, 7i). These data indicate that pre-artery specification occurs in the coronary plexus between E12.5 and E14.5, creating a progenitor pool that forms virtually all of the embryonic left and right coronary artery branches.
We next investigated whether the artery tips that did not form from pre-artery cells ( Fig. 2f ) arose from pre-existing arteries or through capillary differentiation. Induction of ApjCreER and Cx40CreER labelling at P2 revealed that artery tips at P6 were composed of ApjCreER-lineage cells but depleted of Cx40CreER-labelled cells (Extended Data Fig. 6k ). Thus, postnatal artery tips grow by capillary arterialization.
The morphogenic changes that accompany coronary artery remodelling are seen after blood flow has been established, and are thought to be triggered by shear stress 9, 10 . In E13.5 Isl1 mutant mice that have delayed blood flow 23 , pre-artery cells had congregated in the region where the coronary artery would eventually form ( Fig. 2g ) and began to increase Article reSeArcH lumen size ( Fig. 2h ). Therefore, pre-artery cells within the plexus can differentiate and initiate remodelling before cues from blood flow.
Gradual cell fate conversion
To investigate the vein-to-artery conversion, single cells along the SVc-coronary vessel plexus-pre-artery developmental transition were projected onto a linear continuum ( Fig. 3a, b ). Gene expression was then visualized by LOESS regression (Fig. 3b -e, g and Extended Data Fig. 8a ).
There was a progressive decrease in venous identity as cells exited the SV and moved towards pre-artery (see Coup-tf2, EphB4 and Tie-2 (also known as Tek); Fig. 3b ). A sharp decrease in venous genes was seen in cells that had undergone full pre-artery specification (see and Apj (also known as Aplnr); Fig. 3b ). Arterial gene expression showed two patterns: 'early' genes, expression of which progressively increased in coronary vessel plexus and pre-artery cells ( Fig. 3c and Extended Data Fig. 8a ), and 'late' genes, expression of which was low in coronary vessel plexus, but increased sharply in pre-artery cells ( Fig. 3d and Extended Data Fig. 8a ). Notch ligands and receptors were early genes, with the exception of Hey1, which increased sharply in preartery cells ( Fig. 3e and Extended Data Fig. 8a ). These findings suggest that the loss of venous identity is initially gradual with a progressive increase in arterial identity, and that pre-artery specification occurs after a threshold of venous loss and arterial gain has been achieved ( Fig. 3f ). Cell cycle genes 
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To understand the pre-artery threshold, we performed pathway analysis using gene set enrichment analysis (GSEA) 24 . Most pathways that were enriched in plexus over arterial cells were associated with cell cycling (Extended Data Fig. 8b ). Arterial cells are thought to leave the cell cycle in response to blood flow [25] [26] [27] ; however, pre-artery cells collected before blood flow displayed a decrease in cell cycle genes ( Fig. 3g , Extended Data Fig. 8c , and Supplementary Table 2 ). In vivo, pre-artery cells were less proliferative than the surrounding plexus (Extended Data Fig. 8d ). Thus, decreased proliferation in arteries is acquired during pre-artery specification, and not specifically in response to blood flow.
COUP-TF2 blocks artery formation
To investigate whether pre-artery specification was necessary for artery formation, we required a tool to block this process. We tested COUP-TF2 because it induces venous fate and antagonizes arterial fate 1, 28 and was sharply decreased in pre-artery cells (Figs. 1d, 3b). ApjCreER mice were crossed to mice that constitutively express Coup-tf2 after Cre recombination 29 (Extended Data Fig. 9a ) and pregnant dams were treated with tamoxifen to induce overexpression of Coup-tf2 (Coup-tf2 OE ) before pre-artery specification. Cre recombination of the Coup-tf2 OE allele was low, making this experiment a mosaic analysis in which Coup-tf OE cells were followed within wild-type tissue (Extended Data Fig. 9b, c) .
Coup-tf2 OE cells were present in capillaries and veins, but not arteries ( Fig. 4a , b, top and Extended Data Fig. 9d ). By contrast, control GFP + cells were found in arteries, capillaries, and veins ( Fig. 4a, b , bottom). Coup-tf2 OE cells could survive in arteries when VE-cadherin-CreER induced recombination after arteries had formed (Extended Data Fig. 9e ). Coup-tf2 OE cells could also migrate normally onto the heart (Extended Data Fig. 9f -h), although they caused a mild increase in vessel density at E13.5 (Extended Data Fig. 9g ). Thus, forced COUP-TF2 expression before pre-artery specification blocks cells from contributing to coronary arteries, suggesting a failure to acquire pre-artery fate.
Induction of Coup-tf2 OE after pre-artery specification with Cx40CreER (tamoxifen at E11.5 or E12.5) resulted in numerous Coup-tf2 OE cells within the artery ( Fig. 4c , d, and Extended Data Fig. 9i ) that expressed the arterial markers CXCR4 and JAG1 ( Fig. 4c and Extended Data Fig. 9i ). Therefore, Coup-tf2 OE inhibits arterial fate only before pre-artery specification. Pre-artery specification was then blocked throughout the entire coronary plexus by inducing widespread Coup-tf2 OE recombination using Cdh5CreER (tamoxifen at E11.5 and E13.5). This resulted in small or completely absent coronary arteries ( Fig. 4e, f) . By contrast, induction of Cdh5CreER-Coup-tf2 OE after pre-artery specification, but before arterial morphogenesis (tamoxifen at E13.5 and E15.5), resulted in relatively normal artery development, confirming that the later steps in artery formation are not greatly inhibited by COUP-TF2 ( Fig. 4g ). Thus, pre-artery specification is required for artery development, and this is the specific differentiation step that is antagonized by COUP-TF2 ( Fig. 4h ).
COUP-TF2 inhibits pre-artery via cell cycle genes
We next used scRNA-seq to compare control and Coup-tf2 OE cells. E14.5 coronary endothelial cells (Extended Data Fig. 10a ) were analysed as described for E12.5. Coup-tf2 OE cells were identified by the expression of the transgene's FLAG-myc tag (Extended Data Fig. 10b , c). rPCA revealed a transcriptional continuum linking venous, coronary vessel plexus, and arterial cells ( Fig. 5a, b 
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described for coronary veins 4, 30 . Superimposing transgenic cells onto the control continuum showed that Coup-tf2 OE cells were excluded only from the arterial population ( Fig. 5c ). Venous and arterial genes along the continuum were not generally inhibited by Coup-tf2 OE (Fig. 5a, d and Extended Data Fig. 10d ). The defect instead was in the number of fully pre-artery or arterial cells, as shown with genes such as Cxcr4 and Cx40 (Fig. 5a ). Analysis of differential gene expression did not reveal marked changes in the expression of Notch genes, despite the prevailing theory that COUP-TF2 functions by antagonizing this pathway ( Fig. 5a, d , Extended Data Fig. 10d and Supplementary Table 3 ). Furthermore, overexpression of Notch signalling did not rescue the Coup-tf2 OE phenotype (Extended Data Fig. 9j, k) . It is possible that expression levels were not high enough to overcome COUP-TF2. Instead, a prominent feature of Coup-tf2 OE cells was an increase in cell cycle gene expression (Supplementary Table 3 ). Plotting coronary vessel plexus and vein cells according to G1/S/G2/M cell cycle staging revealed that the Coup-tf2 OE population contained more cells with a cycling profile when compared to controls (Fig. 5e ).
COUP-TF2 also influenced coronary vessel proliferation. The relative increase in Coup-tf2 OE cells over developmental time was greater than for controls ( Fig. 5f ). Endothelial deletion of one copy of Coup-tf2 resulted in decreased proliferation and expansion of coronary vessels ( Fig. 5g and Extended Data Fig. 10e ). As pre-artery specification was associated with decreased proliferation, these data suggest that COUP-TF2 may block arterial specification by activating cell cycle genes.
Next, we sought evidence that cell cycle exit enhances arterial specification, and that COUP-TF2 antagonizes this activity. First, cultured SV sprouts were treated with a cyclin-dependent kinase (CDK) inhibitor, which significantly increased artery differentiation (Extended Data Fig. 9l and m) . Second, a CDK inhibitor was administered to Cdh5CreER Coup-tf2 OE mice dosed with tamoxifen early to assess whether the phenotype of small and absent coronary arteries could be alleviated (see phenotype in Fig. 4f ). Inhibition of CDKs resulted in no significant difference between control and transgenic animals ( Fig. 5h ), demonstrating that the ability of COUP-TF2 to inhibit artery formation had been reversed.
Discussion
scRNA-seq can reveal developmental transitions at a much higher resolution than was previously possible [31] [32] [33] . By combining scRNA-seq with in vivo localization and genetic manipulations, we show that a subset of endothelial cells within the immature coronary plexus crosses a transcriptional threshold to become pre-artery cells. Pre-artery specification is a critical step because blocking this process inhibited artery formation. Prior to pre-artery specification, SV-derived endothelial cells gradually decreased expression of venous genes while gradually increasing expression of arterial genes. These data suggest that fate switching during angiogenesis occurs in a progressive manner, and that individual plexus cells that reach a threshold towards full arterial differentiation form the mature coronary arteries.
Although COUP-TF2 is considered a master regulator of veins, precisely how it brings about venous fate and suppresses artery fate is still under investigation 2 . Single-cell analysis revealed that COUP-TF2 did not push cells towards a venous fate or markedly suppress arterial genes. Instead, COUP-TF2 specifically blocked pre-artery specification, because Coup-tf2 OE induction before the pre-artery stage prevented mature artery development, whereas induction afterwards had little effect. Our data indicate that COUP-TF2 suppresses pre-artery specification by activating cell cycle genes. Recently, retinal artery differentiation has been shown to depend on cell cycle arrest triggered by blood flow, Notch activation, and CX37 (also known as GJA4) 27 . Pre-artery specification was independent of flow, but may engage similar mechanisms. Future experiments should investigate whether this higherresolution understanding of coronary artery differentiation during cardiac angiogenesis could aid the development of regenerative therapies.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0288-7. 37 , CXCR7-GFP (The Jackson Laboratory, C57BL/6-Ackr3 tm1Litt /J, Stock #008591), CXCL12-DsRed (The Jackson Laboratory, Cxcl12 tm2.1Sjm /J, Stock #022458), VE-Cadherin-CreER 38 . All mice were maintained on a mixed background. Timed pregnancies were determined by defining the day on which a plug was found as E0.5. For Cre inductions, tamoxifen (Sigma-Aldrich, T5648) was dissolved in corn oil at a concentration of 20 mg/ml and was injected into the peritoneal cavities of pregnant dams. For cell cycle inhibition, 0.4 mg dinaciclib was dissolved in 2.6% DMSO (in PBS) and was injected into the peritoneal cavities of pregnant dams. Dosing and dissection schedules for individual experiments were: (1) E12.5 single-cell RNA sequencing: tamoxifen on E9.5 and E10.5, dissection on E12.5. (2) E14.5 single-cell RNA sequencing: tamoxifen at E11.5 and E12.5, dissection at E14.5. (3) ApjCreER Coup-tf2 OE experiments: tamoxifen at E9.5 and E10.5, dissected at E14.5 or E15.5 for coronary contribution quantification. Same dosing schedule, but dissected at E11.5 and E14.5 for recombination rate experiment (E11.5 only) and expansion experiment. Same dosing schedule, but dissected at E11.5, E12.5, or E13.5, was used for ventricular coverage visualization; tamoxifen at E11.5 and E12.5, dissected at E15.5 for capillary visualization in Extended Data Fig. 9 . (4) Cx40Creer Coup-tf2 OE experiments: tamoxifen at E11.5 and E12.5 or E13.5, dissected at E15.5; for Extended Data Fig. 9i : tamoxifen at E11.5, dissected at E15.5. (5) Cdh5CreER Coup-tf2 OE before pre-artery: tamoxifen at E11.5 and E13.5, dissected at E15.5. (6) Cdh5CreER Coup-tf2 OE after pre-artery: tamoxifen at E13.5 and E15.5, dissected at E16.5. (7) Cdh5CreER Coup-tf2 OE dinaciclib experiment: tamoxifen at E11.5 and E13.5, dinaciclib at E12.5, dissected at E15.5. For additional Cx40Creer Rosa tdTomato embryonic lineage-tracing experiment, pregnant dams were dosed via oral gavage with 1 mg 4-OH tamoxifen (Sigma-Aldrich H6278) at E11.5 and dissected at E12.5 (Extended Data Fig. 6f ) or E15.5 (Fig. 2) .
For postnatal lineage tracing at P2 and P6, tamoxifen was injected into the peritoneal cavity of the mother when the neonates were at P2 so that tamoxifen could be passed from the mother to the neonates through milk.
No statistical methods were used to predetermine sample size. For in vitro experiments, cultures were randomly chosen for different treatments and experiments were performed multiple times. Randomization was not relevant to our mouse experiments because genotypes/groups were determined by mouse genetics. Blinding was used in scRNA-seq and mouse experiments, except for lineage tracing, EdU experiments, Coup-TF2 OE cell quantification and NICD quantification, where blinding was not possible because cells positive for certain markers (MYC tag, GFP, tdTomato, EdU) revealed the identities of the samples. Cell isolation for scRNA-seq. E12.5 scRNA-seq. SV-derived cells were captured by fluorescence-activated cell sorting (FACS) of ApjCreER lineage-labelled cells (Cre expressed in SV). An experiment was performed once in which male ApjCreER Rosa mTmG mice were crossed to CD1 females, who were dosed with tamoxifen at E9.5 and E10.5. Embryos were removed and placed into cold, sterile PBS at E12.5. The SVs of each of 27 GFP-positive hearts were microdissected away from the ventricles and pooled into a 300-μl mix consisting of 500 U/ml collagenase IV (Worthington #LS004186), 1.2 U/ml dispase (Worthington #LS02100), 32 U/ml DNase I (Worthington #LS002007), and sterile DPBS with Mg 2+ and Ca 2+ . The ventricles of the 27 hearts were minced with forceps and pooled together in another 300 μl of the aforementioned mix. The pooled SVs and ventricles were then incubated at 37 °C, and gently resuspended every 7 min. After the incubation, 60 μl cold FBS followed by 1,200 μl cold sterile PBS were added and mixed into each tube. The samples were then filtered through a 70-μm cell strainer; the filter and the source tube were washed with a total of 1,200 μl sterile PBS. Cells were then centrifuged at 400g at 4 °C for 5 min. Each cell pellet was then gently resuspended in 600 μl 3% FBS (in sterile PBS). Cells were centrifuged again at 400g at 4 °C for 5 min. Each pellet was then gently resuspended in 2,000 μl 3% FBS and 32 U/ml DNase I in sterile PBS. Cells were kept on ice until they were used for FACS. DAPI (1.1 μM) was added to the cells immediately before FACS. Single cells with a low DAPI signal, moderate PE-Texas Red signal and the highest Alexa-Fluor 488 signal were sorted using Aria II SORP (BD Biosciences). Each cell was sorted into a separate well of a 96-well plate containing 4 μl lysis buffer. Cells were spun down after sorting and stored at −80 °C until cDNA synthesis. A total of 480 SV cells and 480 ventricular cells were sorted and processed for cDNA synthesis. Cells were analysed on the AATI 96-capillary fragment analyser, and a total of 915 cells that had sufficient cDNA concentration were barcoded and pooled for sequencing.
E14.5 scRNA-seq. The experiment was performed once following the same procedure as for E12.5 above unless otherwise noted here.
One thousand, one hundred and fifty-two FACS-captured coronary cells lineage-labelled with ApjCreER were collected from E14.5 hearts (SV cells were excluded and the later time point used to ensure sufficient numbers of Coup-tf2 OE cells). To isolate Coup-tf2 OE cells, male ApjCreER Coup-tf2 OE mice were crossed to Rosa mTmG females who were dosed with tamoxifen at E11.5 and E12.5 and the embryos removed at E14.5. A total of 16 GFP-positive embryos from four litters were dissected for cell isolation and FACS. To isolate wild-type cells, male ApjCreER Rosa mTmG mice were crossed to CD1 females. Pregnant dams were dosed with tamoxifen at E11.5 and E12.5 and embryos removed at E14.5. A total of 12 GFP-positive embryos from three litters were sorted out and further dissected. For both the wild-type and the Coup-tf2 OE samples, a few GFP-negative embryos were processed for dissection and cell isolation in the exact same manner to serve as a negative control for the GFP signal during FACS.
Cells with the highest Alexa-Fluor 488 signal, low DAPI signal, and low PE-Texas Red signal were sorted into lysis buffer. For Coup-tf2 OE , a total of 861 cells were sorted and processed for cDNA synthesis. For wild-type, a total of 608 cells were sorted and processed for cDNA synthesis. Of these, 1,152 passed cDNA fragment quality control (concentration >0.05 ng/μl) and were sequenced. Of those, 1,126 passed QC threshold (>1,000 genes, 10 5 mm10-aligned reads). In Coup-tf2 OE embryos, 326 cells expressed the FLAG-Myc transgene and were compared to the 423 control cells that passed QC. cDNA synthesis and library preparation for scRNA-seq. We used Smart-seq2 to perform scRNA-seq 39 . Poly-A mRNA in the cell lysate was converted to cDNA and amplified as described 39 . Amplified cDNA in each well was quantified using a high-throughput fragment analyser (Advanced Analytical). After quantification, cDNA from each well was normalized to the desired concentration range (0.05-0.16 ng/μl) by dilution, consolidated into a 384-well plate, and subsequently used for library preparation (Nextera XT kit; Illumina) using a semiautomated pipeline as described 40, 41 . The distinct libraries resulting from each well were pooled, cleaned-up and size-selected using precisely 0.6× to 0.7× volumes of Agencourt AMPure XP beads (Beckman Coulter), as recommended by the Nextera XT protocol (Illumina). A high-sensitivity Bioanalyzer (Agilent) run was used to assess fragment distribution and concentrations of different fragments within the library pool. It is important to note that after pooling the libraries and before sequencing there is no PCR step in our protocol. Pooled libraries were sequenced on NextSeq 500 (Illumina). Demultiplexing and alignment of scRNA-seq reads. The resulting reads were 1) demultiplexed using Illumina's demultiplexing tool bcl2fastq (default settings), and 2) processed using skewer11 for 3′ quality-trimming, 3′ adaptor-trimming, and removal of degenerate reads, as described 9 . The processed reads were mapped to the mouse genome (mm10) using STAR (https://github.com/alexdobin/STAR) and gene expression was quantified with HTSeq (http://htseq.readthedocs.io/en/ release_0.9.1/). The expression of the Coup-TFII-OE transgene was quantified by aligning reads to the following sequence, encoding the FLAG-Myc t ag : T AA GCT TCGTATATACCTTTCTATACGAAGTTGTGGATCTGCGATCTAAGTAAGC CGCGGCCATGGACTACAAGGATGACGATGACAAGGCCGCGGCAACTA GTAAGCTTGCCGCCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGT. Cell subtype discovery with iRPCA. First, low-quality cells were filtered out by the following thresholds: >1,000 genes, <40% rRNA, >10 5 mm10-aligned reads, from 915 sequenced cells. Eight hundred and fourty-three cells passed quality control.
To identify the broad cell subtypes present, in situ hybridization data on 52 genes from the Euroexpress 42 database were compared to expression levels in an rPCA plot of all cell in the data set, excluding erythrocytes (Extended Data Fig. 1j ).
Cell subtypes in the ApjCreER-labelled populations were manually defined using gene expression patterns in manually selected PC plots derived from multiple iterative rounds of rPCA (iRPCA). There were two overall goals of iRPCA. The
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first was to fully describe the cellular subtypes within an scRNA-seq data set while minimizing over-clustering of homogenous populations or continua, clustering based on cell cycle phase or technical artefacts/cell quality, and under-clustering of small subpopulations. The second goal was to preserve continuity or discreteness between subpopulations.
Our pipeline differed from standard pipelines in several ways. First, we used rPCA (rrcov::PcaHubert) in lieu of standard PCA. Second, we replaced default PC scores by those calculated by the sum of top 60 genes: PC.score = PC.pos−PC.neg (Extended Data Fig. 1b, c) . These two parameters were used because they provided more clearly defined separations among cells with unique gene expression patterns (see Extended Data Fig. 1a, b and additional description in main text). Finally, we made frequent use of PC pos/neg biplots, which we defined by: Where g i,p are the top 30 genes by positive loading to the PC and g i,n by negative loading. These were used to identify and exclude cell cycle-associated PCs (described below in Identifying cell cycle-regulated genes) (Extended Data Fig. 1d ) and to inspect for cell doublets (expected to have nearly equal levels, on a log scale, of the top markers for two distinct subpopulations; we did not see any in our data set, possibly owing to strict FACS gating on FSC-W and SSC-W and the large spacing of wells on standard 96-well plates) (Extended Data Fig. 1e ). Cell subtype clusters were assigned through the following process. After removing a small number of erythrocytes, all cells in the data set were used to calculate 15 PCs where the input was all genes minus those in our cell cycle category (see Identifying cell cycle-regulated genes) and the output was PC plots based on the sum of top 60 genes. Among the resulting 15 PC plots, one was manually chosen for further analysis based on the following criteria: 1. cells were well separated among the PC axes; 2. expression patterns of the top 60 genes revealed distinct populations or clusters; and 3. the PC was not highly correlated with cell cycle genes (see Identifying cell cycle-regulated genes) or number of genes detected (that is, technical artefact). Distinct cell populations within the selected PC were manually identified by their separation from other cells within the plots and strong correlation with distinct gene expression patterns. One (or more) distinct cell population was then removed, and another iteration was performed to calculate another set of PCs containing the decreased number of cells. Each of these subsequent iterations similarly involved, first, a PC calculation (10-15 PCs depending on step), then, a manual selection of one PC plot based on the above-described criteria, and, finally, within that selected PC the manual identification or removal of cell subpopulations based on the above-described criteria. These iterations ended when the calculated PCs revealed a single continuum that was arranged in a linear progression on the PC plots, which indicated the presence of only two groups of cells: one with high expression of one set of markers and the other with high expression of a second set of markers (Extended Data Fig. 1k ). These last continua were separated into two groups, which comprised the final clusters. In this way, a single continuum was not overclustered into more than two groups.
Included in the custom R scripts are the exact steps by which we obtained all the reported clusters in the E12.5 data. In the first two rounds, rPCA (rrcov::Pca-Hubert, k = 15) was run using all genes expressed in >1 cell, filtered by removing ribosomal proteins by grep(Rp[ls]*), as well as Rn45s (also known as Rna45s5), Lars2, and Malat1. In all rounds after that, the list of 202 cell cycle genes described below was also removed from the gene list. In total, 20 rounds of iRPCA were performed to cluster cells into the 10 subpopulations in this work. Pairwise discreteness test. To analyse the relationship between pairs of subpopulations of cells, the cells of the two subtypes are first projected onto a single axis of identity. For the purpose of the following description, these populations are referred to as A and B. To do this, cells are scored by their expression of the top differentially expressed genes between the two populations. Differential expression is calculated as log fold change, fractional difference (difference in fraction of A cells expressing minus the fraction of B cells expressing), and Wilcoxon P value; genes are filtered by fold change >0.2 (natural logarithm), fractional difference >0.05, and P < 10 −3 . The top n genes, sorted by fold change and fractional difference, are referred to as g a (top n genes enriched in A) and g b (top n genes enriched in B). The results do not vary much for n between 20 and 100 (Extended Data Fig. 1l , only low-confidence connections change). In this work, the gene list is pre-filtered by removing ribosomal genes (Rp[ls]*) and cell cycle genes (the list of 202 cell cycle genes described below). Cells are then given a score x by their expression of these genes:
Where g is in log 10 counts per million (CPM) units and max is the maximum across all cells in the pair of subtypes. This scores cells along the axis of cell identity along A and B. The resulting distribution of cells along this axis is tested for discreteness, or a lack of intermediate cells, by the width of the largest gap between the two distributions. The statistic is calculated by the following procedure (Extended Data Fig. 1f 
Simulation of population distributions for model validation.
We optimized the cutoffs for the discreteness test using simulated data. The data was simulated by drawing from the five-parameter distribution described above under Estimating the number of intermediate cells, where f AB ranged from 0 to 1 (Extended Data Fig. 1h ). Using the simulations, we found −6 to be a good cutoff for calling cell types discrete-this cutoff is low so as to be sufficiently sensitive to a small number of intermediates (~3 intermediate cells out of 150).
Identifying cell cycle-regulated genes.
When mentioned in the main text, we filtered out a list of 202 cell cycle genes from the input to rPCA to reduce the contribution of cell cycle to heterogeneity. We defined this list by rPCA: cell cycle PCs were identified by high loadings of known cell cycle markers (for example, cyclins, Mki67, Top2a). Also, cell cycle has a unique pattern on PCi.pos versus PCi.neg biplots (described above): there is typically a large coordinated increase in genes upon entering cell cycle with little corresponding decrease in genes, and PCi.pos has low correlation to PCi.neg. The positive and negative loadings were therefore inspected separately for cell cycle genes. In this work, rPCA was performed on a highly cycling, relatively homogeneous subgroup of cells (later identified as SVc and CV) using all genes; we used the union of the top 60 genes by each of the following loadings: PC1-positive, PC2-negative, PC2-negative, PC4-positive, PC5-negative, and PC6-negative, which produced a list of 230 candidate cell cycle genes. We filtered this list for genes that had high loadings to other PCs, marked subpopulations of cells, and had no cell cycle annotation; these included arterial markers such as Unc5b. This produced the final list of 202 cell cycle genes. This list was not complete, but was sufficient to remove cell cycle heterogeneity from the top PCs.
Defining the fetal SVc-CV plexus-arterial axis. We defined the SVc-CV plexusarterial axis (x) using the scores generated by PC2 and PC3 from RPCA on SVc, CV, and arterial cells (Fig. 3a, Extended Data Fig. 4 ) as below:
PC2 score, PC3 score PC2 score 0 4 PC2 score PC3 score , PC3 score PC2 score 0 4 3 2 2 Figure 3a was coloured by the value of this axis. Cell cycle scoring. G1/S and G2/M signatures were discovered in an unbiased manner as follows: coronary vessel plexus cells from wild-type E14.5 animals were analysed with rPCA using all detected genes. Many of the top 60 genes by loading to PC3.neg and PC2.neg were known G1/S markers, and, thus, the G1/S score of a cell was defined by the sum of the scaled expression of these genes. Many of the genes with high loadings to PC4.neg and PC5.neg were known G2/M markers, and the G2/M score was calculated by the sum of the scaled expression of these genes. Cells were scored as cycling if they were not in the bottom-left modes (high expression of at least one cell cycle signature). Seurat clustering for comparison. To compare our clustering to Seurat, we ran Seurat with primarily default options. We filtered our list of 202 cell cycle genes as well as ribosomal proteins from the list of highly variable genes (y.cutoff = 0.5) and ran PCA with 20 scores calculated. Based on the PC elbow plot, we selected the first 10 PCs to be used for clustering. We excluded PC6 for high loading of cell cycle genes (since our list of 202 genes was not exhaustive), and clustered using FindClusters with resolution 2. We also calculated t-SNE, and we used the t-SNE mediods of cell clusters to place the vertices for our results from pairwise PCA (Extended Data Fig. 1l ). Comparison to adult artery-vein continuum. We determined the similarity between our E12.5 endothelial cells and the mature artery-vein continuum as follows. We selected cells from the Tabula Muris data set with the Tissue label 'Heart' and annotation label '1' . We ran PCA on the most variable genes (y.cutoff = 0.35) with the Seurat package. PC2 and PC3 separated cells into three populations along a single continuum, and we projected cells onto a single axis
. Known arterial genes such as Cx40, Cx37, and
Unc5b were negatively correlated, and known capillary/venous markers such as Apj and Nrp2 were positively correlated to the axis, so we considered it to be the artery-vein continuum (AVc). We then calculated the similarity of each fetal cell to each adult cell. To do this, we used as input the union of the top 300 genes correlated to the adult and fetal AVc, smoothed by LOESS regression over the AVc defined above. We calculated the Pearson correlation similarity using these features, and mapped each fetal cell to the adult cell to which it was most similar by this metric.
Immunohistochemistry and Imaging. For whole-mount embryonic hearts. All embryos were fixed in 4% PFA at 4 °C with shaking and washed twice (10 min each wash) with PBS at room temperature with shaking before dissection for wholemount immunostaining. Intact embryonic hearts were washed in PBT (PBS with 0.5% Triton-X 100) at room temperature for one hour before incubation with primary antibodies. Primary antibodies were dissolved in either 5% goat serum or 5% donkey serum in PBT. Hearts were incubated in the solution with primary antibodies with shaking overnight at 4 °C. Hearts were then washed with PBT for six to nine hours with shaking at room temperature, and the wash was changed every hour. Hearts were then stained with secondary antibodies with the same conditions and procedure as for primary antibodies. After washing off the secondary antibodies, hearts were then left in enough PBT to cover them. Two drops of Vectashield (Vector Labs, H1000) were added and mixed with the PBT for each heart, and the hearts were stored at −20 °C for the long term. Imaging was done with Zeiss LSM-700 (10× or 20× objective lens) with Zen 2010 software (Zeiss). For whole-mount postnatal hearts. Hearts were fixed in 4% PFA for 1 h at 4 °C with shaking and washed twice (15 min each wash) with PBS at 4 °C with shaking before dissection for whole-mount immunostaining. In the primary antibodies (diluted in PBT), hearts were shaken at room temperature for 6 h and overnight at 4 °C. To wash the primary antibodies, hearts were shaken in PBT at room temperature for 10 h and overnight at 4 °C. Hearts were washed in 50 ml PBT and the wash was changed every 2 h while shaking at room temperature. Hearts were then placed in secondary antibodies (diluted in PBT) at room temperature with shaking for 6 h and overnight with shaking at 4 °C. Hearts were then washed in 50 ml PBT for 8 h (wash changed every 2 h) and overnight at 4 °C. The washing was repeated for six more days. Prior to imaging, Vectashield (Vector Labs, H1000) was added to hearts in clean tubes, and hearts were equilibrated at room temperature for 40 min. Imaging was done with Zeiss LSM-700 (10× or 20× objective lens) with Zen 2010 software (Zeiss). Primary and secondary antibodies. The following primary antibodies were used at the indicated concentrations: MYC-Tag for COUP-TF2 OE (Cell Signaling Technology, Inc., 2278S, 1:300), VE-Cadherin (BD Pharmingen, 550548, 1:125), VEGFR2 (R&D Systems, AF644, 1:125), CX40 (Alpha Diagnostic International, CX40A, 1:300), ERG (Abcam, ab92513, 1:500), CXCR4 (BD Pharmingen, 551852, 1:125), GFP (Abcam, ab13970, 1:500), VWF (Abcam, ab6994, 1:500), CLDN11 (Abcam, ab53041, 1:1,000), SOX17 (R&D Systems, AF1924, 1:500), anti-actin α-smooth muscle-FITC (Sigma, F3777, 1:200), VEGFR3 (R&D Systems, AF743, 1:125), DACH1 (Proteintech, 10914-1-AP, 1:500), JAG1 (R&D Systems, AF599, 1:125).
All secondary antibodies were Alexa Fluor conjugates (488, 555, 633, 635, 594, 647, Life Technologies, 1:125 or 1:250). DAPI (1 mg/ml) was used at 1:500. In situ hybridization. To identify the broad cell subtypes in the E12.5 single cell data set, expression levels in rPCA plots of 52 genes were compared to in situ hybridization data from the Euroexpress 42 and Allen Brain Atlas databases (stages ranged from E11.5 to E15.5). Expression patterns from E14.5 Euroexpress data are shown in Extended Data Fig. 1i .
For Adm and Fbln2, in situ hybridization on paraffin sections were performed twice as described previously 43 . Antisense Adm and Fbln2 probes were labelled with digoxigenin (DIG)-UTP using the Roche DIG RNA labelling System according to the manufacturer's guidelines.
For Slc45a4, whole hearts were fixed and in situ hybridization performed according to protocol from Additional File 2 of ref. 44 . Probes were Cdh5 (Advanced Cell Diagnostics 312531-C2), Cx40 (Advanced Cell Diagnostics 518041), and Slc45a4 (Advanced Cell Diagnostics 522131-C3). Reagents are RNAscope Protease III & IV Reagents (Advanced Cell Diagnostics 322340) and RNAscope Fluorescent Multiplex Detection Reagents (Advanced Cell Diagnostics 320851). About 12 embryonic hearts were dissected in a sterile and RNase-free environment into a 1.5-ml tube and fixed in 1 ml 4% PFA for 1 h at room temperature. Three fixed hearts were processed in the same tube with 100 μl of the probes master mix. The experiment was performed three times, once each for E13.5 (n = 3), E14.5 (n = 2), and E15.5 (n = 3). SV-atria explant experiment. The experiment was performed three times. In total, 71 embryos were dissected at E12.5. The SV and atria of each embryo were dissected on sterile PBS and gently dropped onto a cell culture insert (EMD Millipore PI8P01250) coated with Matrigel (BD Biosciences) inside a well of a 24-well plate. Two to five explants were cultured onto each insert. Immediately after the explants were dropped onto the insert, 200 μl EGM2-MV medium was added into the space between the insert and the well. The SVs were allowed to attach onto the Matrigel at 37 °C for 2-6 h before another 200 μl EGM2-MV medium was added to the space between the insert and the well. The explants were cultured at 37 °C for approximately 72 h before either flavopiridol or DMSO was added: 900 μl of 40 nM flavopiridol (dissolved in 0.1% DMSO in EGM2-MV) or 0.1% DMSO in EGM2-MV (drug vehicle control) was added to each insert. After addition of either flavopiridol or DMSO, explants were incubated at 37 °C for approximately 48 h before they were fixed and stained.
Each cell culture insert was fixed in 1,000 μl 4% PFA for 2 h at 4 °C without shaking. Then, each insert was washed with 1,000 μl PBS three times at room temperature. Five hundred microlitres of primary antibodies (diluted in 0.5% PBT) were added onto each insert and inserts were incubated at room temperature with shaking for 4-6 h. The inserts were subsequently washed with PBS at room temperature with shaking for 2 h. Five hundred microlitres of secondary antibodies (diluted in 0.5% PBT) were added onto each insert and inserts were incubated at 4 °C for about 16 h. The inserts were then washed with PBS three times at room temperature with shaking for 2 h. The membrane containing the SVs was then excised from the insert and mounted onto a drop of Vectashield on a slide and stored at −20 °C. Imaging was done using a Zeiss LSM-700 (10× or 20× objective lens) with Zen 2010 software (Zeiss).
Article reSeArcH
Acquisition and processing of images. All images were acquired with Zen 2010 software (Zeiss). Images were prepared using Photoshop CS6 (Adobe). Any changes to brightness and contrast were applied equally across the entire image. In vivo EdU Assay. To measure in vivo proliferation rate, 50 μg/g body weight of EdU was injected into pregnant mice intraperitoneally 2-3 h before embryo collection. EdU-positive cells were detected using a Click-iT EdU kit (Invitrogen, C10338) according to the manufacturer's instructions. In brief, Click-iT reaction cocktails were incubated for 30 min after the secondary antibody incubation of the immunostaining protocol. 
Extended Data Fig. 1 | Single cell analysis of ApjCreER lineage labelled cells. a, Comparison of rPCA and classical PCA at separation of subpopulations. PC scores were selected to best separate the Enpp + Esam − population. Cells are coloured by expression (log 10 CPM, scaled to maximum per gene). n = 352 cells. b, Comparison of default and sum-of-60 modified PC scores. PC2 is the default PC score from rPCA; PC2.score is the modified sum-of-top-60 scores (expression is log 10 CPM, scaled to maximum). Y-axis is the number of genes detected per cell (>1 count). n = 426 cells. c, Comparison of default and sum-of-top-60 scores. Scores were chosen that best separated the Vwf + and Cxcr4 populations . 
Extended Data Fig. 3 | Characterization of pre-artery cells. a-d , rPCA plots of the E12.5 SVc-CV continuum. Each dot is an individual cell, and gene expression levels are indicated by the colour spectrum as shown in Fig. 1d , which reflects log 10 CPM. a, Arterial genes highly enriched in the arterial areas of the plot. b, Arterial genes significantly upregulated in, but not specific to, the arterial area of the plot. c, Venous genes highly depleted in the arterial areas of the plot. d, Venous genes downregulated, but not depleted, in the arterial area of the plot. For a-d, Bonferroniadjusted P < 0.01; PCA plots, n = 415 cells. Centre and error bars are mean ± s.e.m. of log CPM expression values. e, Genes expressed in adult coronary artery cells. Data are from the Tubula Muris consortium. n = 445 cells. f, Assignment of artery, capillary, and vein in adult coronary cells based on gene expression enrichment in e. n = 445 cells. g, Schematic for comparing E12.5 coronary cells to those along the adult artery-capillaryvein continuum. h, Results of experiment schematized in g. The centre line correspond to the median; the upper and lower hinges correspond to the first and third quartile, respectively; the whiskers extend to the largest value or to 1.5 × IQR (inter-quartile range, or distance between quartiles), whichever is smaller. Pre-artery cells: n = 20 cells. CV: n = 277 cells. P = 6.2 × 10 −13 . Statistical test is two-tailed.
Extended Data Fig. 5 | Additional whole mount immunofluorescence of marker genes. a, CX40 whole-mount immunohistochemistry in late gestation hearts (E17.5). CX40 is expressed only in cells lining large arteries and arterioles (overlapping blue and green signal). Low level, non-arterial signal is in myocardial cells. b, rPCA plots from E12.5 and E14.5 with accompanying whole-mount immunofluorescence in E13.5 hearts. VWF is enriched in the SV; while APLN-nlacZ signal and DACH1 are present throughout the coronary plexus. CXCR4, ACKR3-GFP, and CXCL12-DsRed are enriched in the pre-artery and artery areas of rPCA plots and are interspersed within the intramyocardial coronary plexus. n = 415 cells (left, E12.5); n = 347 cells (right, E14.5). Scale bars, 100 μm.
Extended Data Fig. 6 | Clustering and additional lineage analysis of pre-artery cells. a, Clusters and relationships generated by rPCA and the pairwise discreteness test (left) and clusters generated by the Seurat pipeline (Louvain/SNN clustering, resolution = 2) (right). n = 757 cells. b, Violin plots show that arterial gene enrichment and venous gene deenrichment are better with manual, iterative clustering, suggesting that this method leads to more precise populations. c, Violin plots of cell cycle genes in the two CV plexus clusters generated by the indicated algorithms. Seurat clusters are more defined by cell cycle differences than iterative rPCA (iRPCA) clusters. b, c, Violin plots were made using Seurat VlnPlot. Each violin plot is one subtype and each dot corresponds to a cell. d, Quantification of SV and endocardium contributions to coronary arteries. Error bars show s.d. ApjCreER RCA: n = 11 hearts. ApjCreER LCA: n = 6 hearts. Nfatc1Cre RCA: n = 5 hearts. Nfatc1Cre LCA: n = 5 hearts. Centre, mean. e, Experimental design to lineage trace pre-artery cells. f, Lineage labelling in E12.5 Cx40CreER Rosa tdtomato hearts induced with tamoxifen at E11.5. g, Arterial lineage labelling in hearts induced at E10.5. h, Example of clones in Cx40CreER Rosa confetti heart at E15.5. Tamoxifen was administered at E12.5. Two groups of cells sharing the same fluorescent label (clones) are present: YFP-labelled (yellow circle) and nGFP labelled (green circle). Clone sizes are very small, consistent with low proliferation rates in pre-arterial cells. i, P8 heart lineage from Cx40CreER Rosa tdtomato mice dosed with tamoxifen at E11.5. Heavy lineage labelling of the left coronary artery is shown (LCA). Arrowheads indicate branches of the right coronary artery. Myocardium (myo) of the left ventricle is also Cx40 + at E11.5, and is also lineage labelled. j, Images from P8 Cx40CreER Rosa tdtomato hearts dosed with tamoxifen at E11.5 or E16.5. Only the E11.5 dosage results in capillary labelling (arrows) resulting from reversion of pre-artery cells that differentiate during the burst of pre-artery specification between E12.5 and E14.5. Arrowheads point to arterial lineage labelling. k, Postnatal lineage tracing in ApjCreER Rosa tdtomato or Cx40CreER Rosa tdtomato hearts where tamoxifen was injected at P2. Tips of arteries are lineage labelled with ApjCreER Rosa tdtomato , but are depleted of Cx40CreER Rosa tdtomato label, indicating that artery tips can extend by incorporating capillary cells that differentiate into arterial endothelial cells. Unpaired two-tailed t-test was used to calculate P values. For ApjCreER, n = 78 artery tips at P2, n = 41 artery tips at P6. P = 4.4608 × 10 −19 . For Cx40CreER, n = 81 artery tips at P2, n = 49 artery tips at P6. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
Zeiss Zen 2010 was used to collect the confocal images. FlowJo version 10 was used to collect flow cytometry data.
Data analysis
Adobe Photoshop CS6, Microsoft Excel 2010/2016, GraphPad Prism 6, Zeiss Zen 2010, and NIH ImageJ 2.0.0 were commercially available softwares used to analyze confocal images. For GSEA, GSEA 3.0 (http://software.broadinstitute.org/gsea/index.jsp) was the commercially available software used. For analysis of single cell RNA-seq results, algorithms were described in Methods and were executed in the commercially available software R using custom scripts (www.r-project.org). Custom scripts are available on GitHub (https://github.com/ gmstanle/coronary-progenitor-scRNAseq). Reads were aligned using STAR 2.6 (https://github.com/alexdobin/STAR) and gene expression was quantified with HTSeq 0.9.1 (http://htseq.readthedocs.io/en/release_0.9.1/). For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Study design
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Sample size
For single cell RNA-seq, the sample sizes were the maximum number of cells we could isolate. The number of cells analyzed were sufficient because their numbers were high and isolated from multiple embryonic hearts from different litters. Furthermore, they provided statistically significant gene expression differences among subpopulations. Based on previous experience with similar experiments, these sample sizes were sufficient.
For quantification of in vivo experiment, the sample sizes were dictated by mouse genetics. Crosses were performed until between 2-20 noncontrol, experimental animals (i.e. mutants) from multiple litters were obtained. Experimental animals were always compared to litter mate controls. Sample sizes were sufficient because the quantification revealed significant differences as assessed by t-test, and in many cases the phenotype was complete (see ApjCreER.COUP-TF2 overexpression). Based previous experience with similar studies, the sample sizes were sufficient.
Data exclusions No data was excluded.
Replication
The results were reproducible for each experimental outcome reported except for the noted here. The following experiments were not replicated: 1) Fbln2 and Adm in situ hybridization was performed once, but different histological slides within the experiment show the same result. 2) Extended Data Figure 6j , e16.5 dosage experiment was performed once, but a similar experiment in Extended Data Fig. 7i show a similar result when harvested at e17.5. 3) Nfatc1Cre LCA and RCA lineage trace was performed once with quantification; however, it is known from References #7 and 8 that both endocardium and SV give rise to coronary vessels. Furthermore, it is known from Sharma et al. 2017 (Dev. Cell, "Alternative Progenitor Cells Compensate to Rebuild the Coronary Vasculature in Elabela-and Apj-Deficient Hearts") that the SV and the endocardium gives rise to vessels in complementary regions of the heart and that they compensate each other's growth. 4) For measurement of ventricular coverage in Coup-tf2 OE hearts, even though it was only quantified once, the same result was observed twice visually without quantification.
Randomization For in vitro experiments, cultures were randomly chosen for different treatments and experiments were performed multiple times. This is not relevant to our mouse experiments because genotypes/groups were determined by mouse genetics.
Blinding
For single cell RNA-seq experiments, blinding occurred because: 1. Analysis was performed using unbiased computational methods and 2. The computational biologist created the majority of transcriptional maps without prior knowledge of coronary vascular biology.
For mouse experiments, blinding was used in that samples were quantified without knowledge of the genotype. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
All samples are from embryonic hearts. Sample preparation protocol is in Methods: Embryos were harvested into cold, sterile PBS at e12.5. The SVs of each of GFP-positive hearts were microdissected away from the ventricles and pooled into a 300 μL mix consisting of 500 U/mL collagenase IV (Worthington #LS004186), 1.2 U/mL dispase (Worthington #LS02100), 32 U/mL DNase I (Worthington #LS002007), and sterile DPBS with Mg2+ and Ca2+. The ventricles of the hearts were minced with forceps and pooled together in another 300 μL of the aforementioned mix. The pooled SVs and ventricles were then incubated at 37C, and gently resuspended every 7 minutes. After the incubation, 60 μL cold FBS followed by 1200 μL cold sterile PBS were added and mixed into each tube. The samples were then filtered through a 70 um cell strainer; the filter and the source tube was washed with a total of 1200 μL sterile PBS. Cells were then centrifuged at 400 g at 4C for 5 minutes. Each cell pellet was then gently resuspended in 600 μL 3% FBS (in sterile PBS). Cells were centrifuged again at 400 g at 4C for 5 minutes. Each pellet was then gently resuspended in 2000 μL of 3% FBS and 32 u/mL DNase I in sterile PBS. Cells were kept on ice until FACS procedure. 1.1 uM DAPI was added to the cells right before FACS.
Instrument
Aria II SORP (BD Biosciences)
Software FlowJo version 10
Cell population abundance For e12.5 SV/atria, post-sort cells represent 0.83% of total cell population; for e12.5 ventricle, 0.31%; for e14.5 wildtype 5.59%; for e14.5 Coup-tf2 OE, 4.49%. The purity of GFP-positive population is high because only cells with the highest 488 fluorescence were selected for sorting (see Gating strategy below).
Gating strategy
Cells were first gated three rounds with SSC and FSC to exclude debris and doublets. Then, DAPI-negative cells were selected to exclude dead cells. For e12.5, cells with the highest 488 fluorescence were then selected for sorting. For e14.5, cells with low PE-Texas Red were selected and subjected to a further round of gating for cells with highest 488 fluorescence for sorting. The preliminary FSC/SSC gates and the boundaries of the positive cells are labeled in red in Supplementary Data 1.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
